« Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier? ». Canadian IBD Today 1, no. S05 (mai 11, 2023): 2–7. Consulté le mars 31, 2026. https://canadianibdtoday.com/article/view/1-s05-ma.